Navigation Links
Two New Tuberculosis (TB) Drugs Show Significant Synergy In Vitro
Date:7/26/2010

ROCKVILLE, Md., July 26 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company developing drugs for treatment of life-threatening infectious diseases, announced today the publication of studies in the scientific journal Antimicrobial Agents and Chemotherapy on synergy between SQ109, its lead drug candidate for the treatment of TB, and TMC207, Tibotec lead TB drug candidate:

Reddy, V.M., L. Einck, K. Andries, and C.A. Nacy. In Vitro Interactions between New Antitubercular Drug Candidates SQ109 and TMC207. Antimicrob. Agents Chemother. 54:2840-2846, Vol. 7, July 2010.

The results of the studies, a research collaboration between Sequella and Tibotec, demonstrated that the combination of SQ109 with TMC207 decreased  the TMC207 minimal inhibitory concentration (MIC) by 4- to 8-fold for the etiologic agent of TB, Mycobacterium tuberculosis. SQ109 also improved the rate of killing of TB bacteria over the rate of killing by each single drug, and it extended the drug post antibiotic effect of TMC207 by 4 hours, with no observable antagonistic activities.  The presence of rifampin (RIF) in three-drug combinations did not affect the synergistic activities of SQ109 and TMC207, and SQ109 also significantly decreased the MIC of RIF. SQ109 was active by itself, its activity was improved by TMC207, and it improved the in vitro activities of both RIF and TMC207.

"These results are very encouraging," commented Dr. Carol Nacy, Sequella CEO.  "TMC207 and SQ109 are two of the first new TB drugs in forty years with the potential to form the foundation for a better treatment regimen for TB and MDR-TB patients everywhere. We look forward to the further substantiation of these results during the in vivo phase of our partnership with Tibotec. "

SQ-109 is a new diamine antibiotic intended to replace one or more of the current first-line anti-TB drugs to improve and simplify patient therapy. SQ109 was granted U.S. FDA Fast Track designation and FDA/EMEA Orphan Drug Designation in 2007. SQ109 shows activity against drug sensitive and multi-drug resistant (MDR and XDR) Mycobacterium tuberculosis, the causative agent of TB. SQ109 has successfully completed its Phase I safety studies and will begin its Phase II clinical efficacy program 2H 2010 in a number of sites in Africa.

About Sequella

Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for life-threatening infectious diseases. The company leverages its global influence, R&D platforms, and disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity.

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law.

For more information contact: Alan S. Klein (alanklein@sequella.com), Executive Vice President, Corporate Development


'/>"/>
SOURCE Sequella, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control
2. Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
3. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
4. Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin
5. CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas
6. New CDC Guidelines Prefer Use of Blood Tests, Including QuantiFERON®-TB, to Diagnose Tuberculosis Infection in Certain Populations
7. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
8. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016 True Health Diagnostics ... leading-edge laboratory services and management expertise to hospital ... , allowing more doctors and patients to benefit ... solutions. Logo - http://photos.prnewswire.com/prnh/20161208/447162LOGO ... systems, under pressure to contain costs, have struggled ...
(Date:12/8/2016)... Research and Markets has announced the addition ... ... The global chromatography market to grow at a CAGR of ... has been prepared based on an in-depth market analysis with inputs from ... over the coming years. The report also includes a discussion of the ...
(Date:12/8/2016)... India , December 8, 2016 ... report "Sugar-Based Excipients Market by Product (Actual Sugars, ... Functionality (Filler & Diluent, Tonicity Agents), Formulation (Oral, ... by MarketsandMarkets, the market has witnessed healthy growth ... grow at a CAGR of 4.3% between 2016 ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, N.Y., Nov. ... adherence to the highest standards of trauma, maternity, cancer and chronic obstructive pulmonary ... and CEO, Dr. Daniel Messina. , Among the recognitions, the American College of ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Care Act. Dr. Botelho advocates for the mass media launching of story movements ... ongoing opportunities to share their unfortunate experiences; such a movement can generate the ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dan ... headquartered in Jefferson County, is announcing the launch of a charity drive to ... number of homeless women and children in Birmingham has grown steadily since the ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and financial consulting services to residential and commercial clients in the northern Alabama ... support for Nobis Works. , Since 1977, Nobis Works has built a network ...
(Date:12/7/2016)... VA (PRWEB) , ... December 07, 2016 , ... ... are celebrating the passage of the most comprehensive mental health systems reform legislation ... the support of the President, and the commitment of our elected officials to ...
Breaking Medicine News(10 mins):